Tominersen

Phase 2RNA therapy

Roche

Tominersen is one of 19 small molecule programs targeting Huntington disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Huntington DiseaseActive, not recruiting

Huntington DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

19 competitors in Huntington Disease

#DrugCompanyPhaseTrials

Epidiolex

Actigall

Dojolvi

Risperdal

Haldol

Minocin

Glucophage

Tricor

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—10

Rilutek

AAzurity Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Huntington Disease

NCT05686551

Clinical

Trials by Indication[1]

Huntington disease1 trial

A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington's Disease

Active, not recruiting· Roche logo

Roche·Phase 2·NCT05686551·301 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Tominersen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tominersen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tominersen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Phase 2[1]
Company: Roche

Tominersen

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Huntington disease1 trial

References

Drug Info

Quick Facts

Related News